Navigation Links
PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
Date:9/1/2010

a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:--  The expected rate of growth in royalty-bearing product sales by PDL's
existing licensees;
--  The relative mix of royalty-bearing Genentech products manufactured and sold
outside the U.S. versus manufactured or sold in the U.S.;
--  The ability of our licensees to receive regulatory approvals to market
and launch new royalty-bearing products and whether such products, if
launched, will be commercially successful;
--  Changes in any of the other assumptions on which PDL's projected royalty
revenues are based;
--  The outcome of pending litigation or disputes; and
--  The failure of licensees to comply with existing license agreements,
including any failure to pay royalties due.Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be ob
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reportlinker Adds Advances in Biopharmaceutical Technology in China
2. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
3. Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
4. Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life
5. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
6. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
7. Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13
8. IntraLinks Announces Partnership With SAFE-BioPharma; Will Provide Digital Identity Capabilities With its Life Sciences Solutions
9. PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010
10. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
11. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor ... in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
(Date:7/30/2015)... WARRINGTON, Pa. , July 30, 2015 /PRNewswire/ ... announced that it has received the second $1.0M ... Business Innovation Research (SBIR) grant valued at up ... the company,s aerosolized KL4 surfactant as a potential ... lung injury.  Discovery Labs was awarded an initial ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... , July 29, 2015 US-Australian drug ... ) today confirmed it is committed to progressing its ... soon as practicable and to ensure the Company delivers ... Executive Officer, Iain Ross , said the Company ... the lead pre-clinical programs, discovery programs and academic partnerships ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... WA, May 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. ... filed an investigational new,drug (IND) application with ... a small molecule phosphatidylinositol-3-kinase (PI-3-kinase),inhibitor for the ... plans to initiate a Phase 1 clinical ...
... produced tiny liquid crystal devices with electrodes made from ... computer and TV displays based on this technology. , ... Dr Kostya Novoselov and colleagues from The School of ... report on the use of graphene as a transparent ...
... SAN DIEGO, April 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ... improving,patient care by developing novel medicines in the ... financial results and highlights for the first,quarter ended ... in both of our development programs,during the first ...
Cached Biology Technology:Oncothyreon files investigational new drug application for PX-866 oncology compound 2Oncothyreon files investigational new drug application for PX-866 oncology compound 3Graphene-based gadgets may be just years away 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 8
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... their genes, yet they differ dramatically in many ways---their walk, ... and language, for example. , Scientists would like to ... from the University of Michigan shows how one process---gene loss---may ... by associate professor of ecology and evolutionary biology Jianzhi Zhang, ...
... connected to the University of Antwerp are the first to ... is a major risk factor for Alzheimer's disease. Amyloid protein ... the senile plaques in the brains of patients. The new ... that is produced, the younger the dementia patient is. ...
... have found that the curry spice turmeric holds ... prostate cancer, particularly when combined with certain vegetables. ... curcumin, along with phenethyl isothiocyanate (PEITC), a naturally ... vegetables that includes watercress, cabbage, winter cress, broccoli, ...
Cached Biology News:Less is more, gene study shows 2Less is more, gene study shows 3Researchers discover a new genetic cause of Alzheimer's disease 2Curry and cauliflower could halt prostate cancer 2
... StabilZyme NOBLE BSA-Free Stabilizer is ... SELECT Stabilizer. It is an ... chemicals in a MOPS buffer (3-(N-Morpholino) ... and contains a combination of 0.02% ...
Mouse monoclonal antibody to PARK2 - Parkinson disease (autosomal recessive, juvenile) 2, parkin...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
Biology Products: